Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
The purpose of this study is to see how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.
For additional eligibility criteria please contact the study team.
For additional study details and procedures will be explained by the study team.
Contact the Study Team
Additional eligibility criteria and study procedures details can be explained by the study team. Please call or email:
- Phone: (352) 273-8675
- Email: email@example.com
Can be done from home
KeywordsNeuroblastoma, Ganglioneuroblastoma, Tumors, Neoplasm, Neuroectodermal
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.